Corpus ID: 178124627

Tratamiento hipouricemiante en la gota: mitos y evidencias

@inproceedings{Ruiz2005TratamientoHE,
  title={Tratamiento hipouricemiante en la gota: mitos y evidencias},
  author={F. P. Ruiz},
  year={2005}
}
  • F. P. Ruiz
  • Published 2005
    • Española del Medicamento, el fármaco de primera elección será el alopurinol. La prescripción de benzbromarona queda restringida a “pacientes que no respondan o no toleren el tratamiento con alopurinol en alguna de estas 3 situaciones: gota severa (poliarticular o tofácea), hiperuricemia en pacientes con insuficiencia renal y aclaramiento de creatinina superior a 20 ml/min e hiperuricemia en pacientes con trasplante renal”. Ante esta situación de prescripción obligada, el clínico puede asumir… CONTINUE READING
    reumatologiaclinica.org
    1 Citations
    One Citation
    Citation Type

    Citation Type

    Tratamiento hipouricemiante en la gota: mitos y evidencias

    References

    SHOWING 1-10 OF 23 REFERENCES
    Clinical evaluation of benzbromarone: a new uricosuric drug.
    • 40
    Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    • 230
    Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study.
    • 125
    Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    • 382
    Improvement of Renal Function in Patients with Chronic Gout after Proper Control of Hyperuricemia and Gouty Bouts
    • 76
    Long-term efficacy of hyperuricaemia treatment in renal transplant patients.
    • F. Pérez-Ruiz, P. Gomez-Ullate, +4 authors J. Nolla
    • Medicine
    • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
    • 2003
    • 46
    • PDF
    The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    • 56
    Correction of Allopurinol Dosing Should Be Based on Clearance of Creatinine, but Not Plasma Creatinine Levels: Another Insight to Allopurinol-Related Toxicity
    • 54
    Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.
    • 169
    The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years.
    • 30